Daphne Roelofs
Research Subjects
Daphne Roelofs has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Dora Hammerl
Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands
28 shared publications - Kim Kroese
Pan Cancer T BV, Rotterdam, the Netherlands
28 shared publications - Mandy van Brakel
Erasmus MC Cancer Institute 4 Department of Medical Oncology Erasmus University Medical Center, Rotterdam, the Netherlands
28 shared publications - Rachel J. M. Abbott
Pan Cancer T BV, Rotterdam, the Netherlands
28 shared publications - Rebecca Wijers
Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands
28 shared publications - Reno Debets
Department of Medical Oncology, Laboratory of Tumor immunology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
28 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Extended phenotypes of intra-tumoral and peripheral T-cells following adoptive transfer of FLY-1A TCR T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Extended phenotypes of intra-tumoral and peripheral T-cells following adoptive transfer of FLY-1A TCR T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary methods from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
This file contains supplementary methods and references.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary methods from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
This file contains supplementary methods and references.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Retrieval of ROPN1/B-specific T-cells and TCR genes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Retrieval of ROPN1/B-specific T-cells and TCR genes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Overview of healthy cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Overview of healthy cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
FLY-1A TCR T-cells recognize patient-derived melanoma cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
FLY-1A TCR T-cells recognize patient-derived melanoma cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
The extent of recognition of the ROPN1 target by FLY-1A TCR T cells correlates with level of expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
The extent of recognition of the ROPN1 target by FLY-1A TCR T cells correlates with level of expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Presence of ROPN1 and FLY-1A TCRβ in metastatic TNBC in relation to endogenous T cell phenotype and anti-PD1 response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Presence of ROPN1 and FLY-1A TCRβ in metastatic TNBC in relation to endogenous T cell phenotype and anti-PD1 response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
FLY-1A TCR T-cells recognize melanoma tumoroids.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
FLY-1A TCR T-cells recognize melanoma tumoroids.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
ROPN1/B peptides identified with immunopeptidomics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
ROPN1/B peptides identified with immunopeptidomics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Expressions of ROPN1/B, NY-ESO1 and MAGE-A4 target antigens in healthy tissues, TNBC and other tumor types.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Expressions of ROPN1/B, NY-ESO1 and MAGE-A4 target antigens in healthy tissues, TNBC and other tumor types.